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ABSTRACT 
 
Background: Male breast cancer is rare and treatment is based on data from females. High 
expression/activity of eukaryotic initiation factor 4E (eIF4E) denotes a poor prognosis in female 
breast cancer, and the eIF4E pathway has been targeted therapeutically. eIF4E activity in female 
breast cancer is deregulated by eIF4E over-expression and by phosphorylation of its binding 
protein, 4E-BP1, which relieves inhibitory association between eIF4E and 4E-BP1. The 
relevance of the eIF4E pathway in male breast cancer is unknown.   
 
Methods: We have assessed expression levels of eIF4E, 4E-BP1, 4E-BP2 and phosphorylated 
4E-BP1 (p4E-BP1) using immunohistochemistry in a large cohort of male breast cancers 
(n=337) and have examined correlations with prognostic factors and survival.  
 
Results: Neither eIF4E expression or estimated eIF4E activity were associated with prognosis. 
However, a highly significant correlation was found between p4E-BP1 expression and disease-
free survival, linking any detectable p4E-BP1 with poor survival (univariate log rank p=0.001; 
multivariate HR 8.8, p=0.0001).  
 
Conclusions: Our data provide no support for direct therapeutic targeting of eIF4E in male 
breast cancer, unlike in females. However, as p4E-BP1 gives powerful prognostic insights that 
are unrelated to eIF4E function, p4E-BP1 may identify male breast cancers potentially suitable 
for therapies directed at the upstream kinase, mTOR. 
 
Keywords: male breast cancer, translational regulation, predictive markers
! ∃!
Introduction 
Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancers 
and less than 1% of all male cancers diagnosed in the UK in 2009 (Cancer Research UK, 2010). 
There is relatively little research into MBC, presumably as a result of its rarity, and much of the 
published work has focused on comparisons with female breast cancer (FBC). Comparisons 
demonstrate that MBC is more likely to be estrogen receptor positive (92% positivity vs 78% 
for FBC (Ruddy & Winer, 2013)), and has some differences in genetic (Johansson et al, 2011; 
Kornegoor et al, 2012; Piscuoglio et al, 2016), transcriptomic (Callari et al, 2011; Johansson et 
al, 2012), and protein expression profiles (Shaaban et al, 2012) (reviewed in (Deb et al, 2016)). 
Incidence trends in terms of geographical location and impact of patient age for both diseases 
are broadly similar (Kreiter et al, 2014). These studies have not given insights that suggest 
different treatment approaches are appropriate, either in terms of which prognostic or predictive 
markers might be useful, or which therapies should be used. Also, there are no prospective 
randomised controlled trials for MBC that could inform treatment decisions (Bratman et al, 
2012). Consequently, MBC management is based on data from FBC. One key difference, 
however, is that the vast majority of MBC patients undergo mastectomies (Korde et al, 2010), 
whereas breast conserving surgery is prevalent for FBC. It is worth noting that this difference is 
not based on evidence concerning treatment outcomes, rather on practical issues relating to the 
size of breast tissue. Adjuvant therapies, including radiotherapy (Ruddy & Winer, 2013), 
tamoxifen (Fogh et al, 2011; Ribeiro & Swindell, 1992) and chemotherapy (Korde et al, 2010), 
are essentially the same. 
 
The eukaryotic translation initiation factor 4E (eIF4E) is a key component of the translational 
machinery and has two specific functions. Firstly, it recognizes and binds to mRNA caps within 
the cytoplasm allowing initiation of cap-dependent translation (Sonenberg, 2008), the 
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mechanism responsible for most protein synthesis (Gray & Wickens, 1998). Secondly, eIF4E 
binds to some mRNAs within the nucleus and regulates their nuclear export (Culjkovic et al, 
2007; Culjkovic et al, 2005). Activity of eIF4E is controlled largely by the eIF4E binding 
proteins (4E-BPs), of which there are three, although only 4E-BP1 and 2 have been studied in 
any detail. eIF4E function is inhibited when bound by 4E-BPs (Matsuo et al, 1997), but this 
interaction is itself regulated by a series of sequential phosphorylations to the 4E-BPs mediated 
via the mTORC1 complex (Gibbons et al, 2009). Phosphorylated 4E-BPs are unable to bind to 
eIF4E. Thus, eIF4E activity is defined by a subtle balance of expression levels of eIF4E and the 
4E-BPs, and the phosphorylation status of the 4E-BPs (Coleman et al, 2009). Activity of eIF4E 
is frequently increased in a wide range of cancers (De Benedetti & Graff, 2004), resulting in 
enhanced translation (and potentially nuclear export) of a subset of mRNAs that contains many 
cancer-related transcripts. In FBC, eIF4E is frequently expressed at higher levels in breast 
cancers compared to normal or benign breast tissue (Kerekatte et al, 1995; Norton et al, 2004) 
and higher levels of eIF4E are associated with poorer prognoses (Byrnes et al, 2006; Li et al, 
2002). In addition, higher levels of the phosphorylated form of 4E-BP1 (p4E-BP1) are also seen 
in FBC compared to normal and benign tissue (Zhou et al, 2004), and these levels are positively 
associated with grade, lymph node metastasis and disease recurrence (Rojo et al, 2007). Our 
own work has demonstrated that combined analysis of expressions of eIF4E, 4E-BP1, 4E-BP2 
and p4E-BP1 predicts breast cancer survival in females and represents an estimate of eIF4E 
activity (Coleman et al, 2009). The influential role that eIF4E plays in neoplasia has made it an 
attractive anti-cancer drug target. Therapeutic approaches that have been explored include 
knock-down of eIF4E expression (Graff et al, 2007; Hong et al, 2011), blocking of eIF4E-cap 
binding (Assouline et al, 2009; Pettersson et al, 2011), inhibition of eIF4E phosphorylation in 
an effort to reduce its activity (Wheater et al, 2010), and - most commonly - inhibition of 
mTORC1 activity leading to 4E-BP hypophosphorylation and inhibitory binding to eIF4E (Chan 
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et al, 2005; Wazir et al, 2014). It should be noted that inhibition of mTORC1, or more generally 
the mTOR kinase component of this complex, clearly has anti-cancer influence that are 
independent of 4E-BP1 through other targets of the complex (Laplante & Sabatini, 2009), and 
therefore this approach is in no way equivalent to direct targeting of eIF4E. Currently nothing is 
known about the prognostic relevance of eIF4E and the 4E-BPs in MBC, and there is no 
evidence base from which novel eIF4E-directed therapies might be considered in this disease; 
our aim was to perform the first investigation of the importance of these molecules in this cancer 
type.  
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Materials and Methods 
 
Patients and tissue microarrays 
Ethical approval was obtained from Leeds (West) (ref 06/Q1205/156) and Leeds (East) 
Research Ethics Committees (ref 05/Q1206/136). Archival resection samples of invasive breast 
cancers from male breast cancer patients (n=337) and associated clinical and pathological data 
were collected from the United Kingdom (157; 46.6%), Italy (50; 14.8%), Hungary (41; 12.2%), 
Poland (30; 9.5%), Canada (50; 14.8%) and Nigeria (9; 2.7%). Clinico-pathological 
characteristics are shown in Table 1. Survival data were available for 187 cases. Tissue 
microarrays (TMAs) were constructed from tissues; this process has been described in detail 
previously (Shaaban et al, 2012). In summary, H+E stained tumour sections were reviewed by 
specialist breast consultant histopathologists (RAM-S, AMH, Dr Abeer Shaaban [Queen 
Elizabeth Hospital, Birmingham, UK]) in order to confirm diagnoses and select representative 
areas of invasive carcinoma from which TMA cores would be taken. TMAs were constructed of 
duplicate or triplicate 0.6mm tumour cores from each individual case. 7 TMA blocks were used 
for the cohort, each including a perimeter wall of non-breast tissue (liver, sheep lung, placenta 
and brain) to minimise edge effects and to provide internal controls. 
  
Immunohistochemistry 
Immunohistochemistry was carried out as previously described (Coleman et al, 2009). In 
summary, 5µm sections were taken from blocks, and were deparaffinised and re-hydrated. 
Appropriate antigen retrieval (see below) was performed and sections were treated with 1% 
hydrogen peroxide-methanol to inhibit endogenous peroxide activity. Sections were stained 
overnight with primary antibodies (see below) diluted in antibody diluent solution (Invitrogen; 
Carlsbad, USA). Signals were visualised using the DAB based Envision System (Dako; 
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Glostrup Denmark). All case TMAs, and a control TMA of female breast cancers, were stained 
for each antibody as a single batch. Female cores served as positive and negative controls. 
Antibodies, dilutions and antigen retrieval: eIF4E (moue monoclonal sc9976; Santa Cruz 
Biotechnology; Santa Cruz, USA; 1:100; 2min pressure cooker in antigen un-masking solution, 
Vector, USA); 4E-BP1 (rabbit polyclonal 9452; Cell Signalling Technology [Danvers, USA]; 
1:100; no antigen retrieval); 4E-BP2 (rabbit polyclonal 2845; Cell Signalling Technology 
[Danvers, USA]; 1:100; 12min full power microwave in pH6 citrate buffer); p4E-BP1 Thr37/46 
(rabbit polyclonal 2855; Cell Signalling Technology [Danvers, USA]; 1:25; 12min full power 
microwave in pH6 citrate buffer). The specificities of these antibodies have been validated 
previously and they have all been used successfully for immunohistochemistry in breast tissue 
previously (Coleman et al, 2009; Satheesha et al, 2011; Zhou et al, 2006).  
 
Scoring and statistics 
Stained TMAs were digitally scanned (Aperio; Oxford, UK), and cores were scored 
independently by two consultant histopathologists (RAM-S, CDS) from the same digital images. 
Cytoplasmic and nuclear immunoreactivity were separated and given individual scores.  The 
scoring system incorporated scores for staining intensity in tumour cells (0 no staining, 1 weak 
staining, 2 moderate staining and 3 strong staining) added to scores for proportions of tumour 
cells staining positively (1 <5%, 2 6-25%, 3 26-75% and 4 >75%), giving totals of either 0 or 
from 2 to 7, as has been used previously for these antigens (Coleman et al, 2009; Zhou et al, 
2006). Analyses were performed in SPSS (SPSS; Chicago, USA) unless stated otherwise. 
Correlations between antigen expression scores and clinical factors were examined by 
calculating Spearman rho correlation coefficients. Associations with disease recurrence and 
survival were analysed by Kaplan-Meir survival curves and log rank tests following ROC curve 
analysis to dichotomise the expression scores into low and high expression appropriately. Kappa 
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calculations were performed using Analyse-it for Excel (Microsoft; Redmond, USA). All tests 
were two-sided.   
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Results 
 
eIF4E, 4E-BP1, 4E-BP2 and p4E-BP1 expression varies widely in male breast cancer 
Tissue microarrays (TMAs) containing duplicate or triplicate samples from 337 male breast 
tumours were stained using immunohistochemistry to analyse expression of eIF4E, 4E-BP1, 4E-
BP2 and p4E-BP1. Cores were scored by two independent histopathologists in terms of 
expression intensity and proportions of cells staining positively. To take into account the 
potentially different roles of these protein species in different cellular compartments (Culjkovic 
et al, 2006; Sonenberg, 2008), cytoplasmic and nuclear immunoreactivity were separated and 
given individual scores. Scores from the two histopathologists were highly concordant, 
demonstrating robust and reproducible scoring; quadratic weighted kappa statistics were 0.85-
0.96 for cytoplasmic scores and 0.74-0.95 for nuclear (depending on antigen; see Table S1). 
Core loss, an expected and documented occurrence in TMA-based research (Parsons & Grabsch, 
2009), or lack of tumour cells meant that staining was not assessable in some cases; however a 
mean of 2.3 cores were successfully scored for each case for each antibody. We analysed 
variability in scores between multiple cores representing individual tumours in order to assess 
potential heterogeneity within individual tumours and therefore the representative nature of 
TMA cores. Spearman’s rho correlation coefficients for duplicate scores for each tumour and 
antigen were all 0.79 (p<0.001) or over, demonstrating that there was relatively little 
heterogeneity in marker expression within individual tumours and that TMA based analyses 
were appropriate. Having determined that inter-scorer and core-to-core variability were low, we 
took mean values of all the scores available for each case/antigen/sub-cellular location to create 
single scores for further analysis. Representative staining and the frequency distributions of 
these scores (rounded to the nearest whole number) are shown in Fig 1. The full range of 
expression patterns were seen for each antigen, ranging from no detectable expression through 
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to strongly expressed in more than 75% of tumour cells. The distributions of cytoplasmic and 
nuclear scores were broadly similar for each antigen, and expressions in the two compartments 
were strongly associated (Spearman’s rho correlation coefficients 0.85 to 0.95, p<0.0008), 
suggesting that separating the two scores gave relatively little additional information.  
 
Expression of eIF4E correlates weakly with ER status in male breast cancer 
Associations between marker expression and established prognostic factors were examined. The 
factors tested were: 1) histological tumour grade (1, 2 or 3); 2) tumour size (categorised as 2cm 
or less, >2cm but less than or equal to 5cm, or >5cm); 3) lymph node status (negative or 
positive); and, 4) oestrogen receptor alpha (ERα) status (negative [Allred 0 or 2] or positive 
[Allred >2]).  Spearman’s rho correlation coefficients (r) were calculated for each potential 
association. The only associations with Spearman’s coefficients >0.2, which is weak at best, 
were both cytoplasmic and nuclear eIF4E expression being positively associated with ERα 
status (r=0.231 and r=0.202 respectively; p<0.002).  
 
Expression of p4E-BP1, but not eIF4E, is strongly associated with male breast cancer 
survival 
Kaplan-Meier survival analyses were performed to determine whether expression of the markers 
was significantly related to disease free survival (DFS). Cut offs were applied to dichotomise 
patients into two groups based on low or high expression of each marker. These cut offs were 
defined objectively using receiver operator curve analyses (Zlobec et al, 2007) to give the best 
balance between sensitivity and specificity for prediction of the relevant clinical outcome (i.e. 
breast cancer recurrence). The cut off values are shown in Table S2. Kaplan-Meier survival 
analyses were performed and log rank tests were used to assess the significance of relationships. 
A stringent value of p<0.003 was defined as indicating significance, after Bonferroni correction 
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for multiple tests from an initial value of p<0.05. Only cytoplasmic expression of p4E-BP1 
demonstrated a significant relationship with survival (Fig 2), with patients with low p4E-BP1 
expression having a longer DFS than those with high expression (215 vs. 95 months, p=0.001). 
It is important to note that the cut off to dichotomise p4E-BP1 expression was 0.83, meaning 
that tumours in the two groups were those without detectable p4E-BP1 (negative) or those with 
any detectable expression (positive). Cytoplasmic and nuclear expression of 4E-BP1, and - 
surprisingly – nuclear expression of 4E-BP2, also showed trends towards significant 
relationships with survival, although these fell short of our stringent significance test. 
Expression of eIF4E itself showed no such trend (Table S3). 
 
Estimated eIF4E activity is not associated with male breast cancer survival 
We have previously demonstrated in FBC that assessments of expression of these markers could 
be combined to estimate eIF4E activity, an estimated value that was significantly associated 
with survival (Coleman et al, 2009). Activity (referred to as “z”) was estimated as X – BP1/4 + 
pBP1/2 – BP2/4, where X represents the eIF4E score, BP1 the 4E-BP1 score, BP2 the 4E-BP2 
score, and pBP1 the p4E-BP1 score. This estimate was determined for these MBC cases using 
the cytoplasmic scores, and receiver operator curve analysis was performed to determine a 
suitable cut off to split the cohort in groups with high and low z scores. Kaplan Meier survival 
analyses were performed. Estimated eIF4E activity was not significantly associated with DFS 
(Table S3).  
 
Cytoplasmic p4E-BP1 is significantly associated with survival in multivariate analysis 
Multivariate regression was performed to assess whether cytoplasmic expression of p4E-BP1 
was an independent prognostic factor with regards to DFS. The other variables put into the 
model were the currently used prognostic factors of grade, tumour size, lymph node status and 
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ERα status.  Both cytoplasmic p4E-BP1 expression and tumour size were significantly 
associated with DFS on univariate and multivariate analyses, although cytoplasmic p4E-BP1 
expression consistently showed the greater significance and the more informative hazard ratio 
(Table 2).  
 
 
  
! ∀∃!
Discussion 
 
This study is the first in which expressions and prognostic relevance of eIF4E and the 4E-BPs 
have been examined in MBC. Our analysis involved one of the largest MBC cohorts assembled 
(n=337) and thorough immunohistochemical analyses with multiple tissue samples per case, 
very robust histopathological scoring, and well-validated antibodies. It is also worth noting that 
our work is the first in any cancer to separately investigate the prognostic worth of eIF4E and its 
regulatory molecules in cytoplasmic and nuclear compartments, in accordance with their 
different reported roles in these locations (De Benedetti & Graff, 2004; Siddiqui & Borden, 
2012). We found expression in these compartments to be tightly correlated, and separate 
prognostic insights were not gained from the compartment analysis. Interestingly, some 
individual cases with prominent nuclear only, or cytoplasmic only expression were noted, 
suggesting that sub-cellular regulation may take place in some circumstances; however cases 
were infrequent and analysis of their common clinicopathological features was flawed on this 
basis. A rare precedent for separating different subcellular localisation of these molecules in 
cancer is, remarkably, also in the context of MBC. Nuclear and cytoplasmic distributions of 
p4E-BP1 have been reported previously in 56 familial MBCs, showing expression in the two 
compartments to be highly associated and positive in 52 and 55% of cases respectively (slightly 
more than we find) (Deb et al, 2013). 
 
Surprisingly, and in marked contrast to FBC (Coleman et al, 2009), no association was found 
between eIF4E expression and survival. Expression of eIF4E has been associated with prognosis 
in a wide range of cancers (De Benedetti & Graff, 2004), but there are specific cancers where 
this is not the case, for example, in acute myeloid leukaemia (Green et al, 2012) or 
osteosarcoma (Osborne et al, 2011). In addition, there is likely to be a publication bias against 
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such findings, so it may be that this lack of association is more common than currently 
appreciated. Strikingly, however, we identified a strong prognostic association for p4E-BP1, 
with any detectable p4E-BP1 expression correlated with poor survival in both univariate and 
multivariate analyses (Fig 2; Table 2). This association was far stronger than previously found 
in FBC (Coleman et al, 2009). 4E-BP1 phosphorylation breaks 4E-BP1’s inhibitory interaction 
with eIF4E resulting in increased eIF4E activity (De Benedetti & Graff, 2004), therefore one 
might expect that p4E-BP1 could only be functionally associated with prognosis through the 
eIF4E pathway. Yet, here we show that the wide variations in expression of eIF4E itself, or in 
estimated eIF4E activity, do not impact on prognosis (Tables S2 and S3) rendering this 
expectation incompatible with our data. We interpret this to suggest that p4E-BP1 is acting as a 
biomarker for functionally-relevant activity of the upstream kinase, the mTORC1 complex, 
rather than having a direct functional impact on prognosis itself.  In support of this, it is well 
established that levels of p4E-BP1 correlate with mTORC1 activity in various contexts, and 
accordingly p4E-BP1 has frequently been used as a pharmacodynamic marker for mTORC1 
activity in trials of mTORC1-targeting therapeutics (Spunt et al, 2011; Tabernero et al, 2008).  
 
The kinase within the mTORC1 complex is mTOR, up-regulation of which is associated with 
development of many cancers (Shaw & Cantley, 2006). The mTORC1 complex acts on a large 
number of different molecular substrates (Hsu et al, 2011; Laplante & Sabatini, 2009), although 
the functional importance of two have been studied in considerably more detail than the others 
with regard to cancer: 4E-BP1 and S6 kinase 1 (S6K1).  In MBC we believe that 4E-BP1 may 
not be a functionally-relevant substrate, therefore it seems likely that deregulated mTOR acts at 
least in part through S6K1 and its downstream effectors. Phosphorylated (activated) S6K1 can 
induce oncogenic increases in overall protein translation, and changes in sterol, lipid and 
mitochondrial metabolism via a variety of complex signalling pathways (Alayev & Holz, 2013). 
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Expression levels of both eIF4E and mTOR have been noted in a previous analysis of gene 
expression profiles in MBC (n=37) as compared to FBC (Callari et al, 2011). Both proteins 
were found to be more highly expressed in MBC than in FBC, and the authors commented that 
the eIF4E pathway may therefore present an attractive therapeutic target in MBC. Our findings 
impact on this suggestion, in that we find eIF4E itself to be unrelated to prognosis, while we 
infer that mTOR activity within the mTORC1 complex may well relate to prognosis. Thus, our 
data do not support use of therapies directed at eIF4E itself, such as knock-down of eIF4E 
expression (Graff et al, 2007; Hong et al, 2011), or function (Assouline et al, 2009; Pettersson 
et al, 2011; Wheater et al, 2010), but do support potential use of therapies directed at the 
upstream kinase, mTOR.  
 
These findings may delineate potential differences in appropriate treatments between female and 
male breast cancers.  For example, the eIF4E-directed therapies LY2275796 (anti-sense 
oligonucleotides directed against eIF4E) and ribavirin (which reduces eIF4E-dependent 
translation) have shown some promise in pre-clinical or clinical trials (Hong et al, 2011; 
Pettersson et al, 2015), and are under-going evaluation for FBC. Our data suggest that these may 
have limited efficacy in MBC since eIF4E activity appears relatively unimportant in 
determining prognosis in this disease. However, by contrast, the growing list of therapies 
targeting mTOR (Sun, 2013), such as everolimus or temsirolimus that have already shown 
promise in FBC trials (Baselga et al, 2012; Wolff et al, 2013), may well be suitable therapies in 
both female and male cancers.  Interestingly, there is a single case report describing a favourable 
response of a MBC patient to temsirolimus (Katayama et al, 2013), but unfortunately it seems 
unlikely that a MBC trial will take place due to the rarity of the disease overall. A further issue 
would be that fewer than 50% of MBC cases expressed detectable p4E-BP1 in our data (Fig 1), 
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and therefore only a minority may potentially be suitable for this approach. Nevertheless, we 
conclude that mTOR-targeted therapies may be worth considering in p4E-BP1 positive MBC.  
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Figures / Tables and legends 
 
 
 
 
 
Figure 1.  Male breast cancer (MBC) has a full range of expression patterns for eIF4E, 4E-BP1, 
4E-BP2 and p4E-BP1. Tissue microarrays containing multiple tumour cores from 337 MBCs 
were stained as indicated using immunohistochemistry. Cytoplasmic and nuclear expressions in 
tumour cells were assessed as 0 (negative) or 2-7 (positive, increasing intensity/proportion of 
positive cells). Representative positive staining is shown at the top of the panel for each antigen. 
Images shown were scored for cytoplasmic, c, and nuclear, n, expression as follows: eIF4E - c 
7, n 6; 4E-BP1 - c 4, n 5; 4E-BP2 - c 5, n 0; p4E-BP1 - c 6, n 3. Frequency distributions of 
cytoplasmic (black) or nuclear (grey) expression across the cohort are shown below. Mean 
scores for each case were determined and are represented rounded to the nearest whole number. 
! ∀)!
 
 
Figure 2. Expression of p4E-BP1 is significantly associated with disease-free survival in male 
breast cancer (p=0.001). Kaplan–Meier survival analyses for patient groups with tumours with 
either no detectable (negative; grey line) or any detectable (positive; black line) expression of 
p4E-BP1. 
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Characteristic 
 
Number (%) 
n=337 
Histological type: 
Ductal no-special type 
Papillary/encysted papillary 
Mucinous 
Lobular  
Other special type 
Mixed 
Unknown 
 
275 (81.6) 
17 (5.1) 
11 (3.3) 
3 (0.9) 
5 (1.5) 
8 (2.4) 
8 (2.4) 
Tumour grade: 
1 
2 
3 
Ungraded 
 
44 (13.1) 
158 (46.9) 
121 (35.9) 
14 (4.2) 
Tumour size: 
1 (<2cm) 
2 (2-5cm) 
3 (>5cm) 
Unknown 
 
70 (20.8) 
65 (19.3) 
14 (4.2) 
188 (55.8) 
LN status: 
At least 1 positive node 
No positive nodes 
Unknown 
 
112 (33.2) 
101 (30.0) 
124 (36.8) 
ER status: 
Positive (Allred score >2) 
Negative 
Unknown 
 
238 (70.6) 
52 (15.4) 
47 (13.9) 
PR status: 
Positive (Allred score >2) 
Negative 
Unknown 
 
238 (70.6) 
48 (14.2) 
51 (15.1) 
 
Table 1. Clinical and pathological features of the cohort. LN – lymph node; ER – oestrogen 
receptor alpha; PR – progesterone receptor 
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 Univariate analysis Multivariate analysis 
Hazard ratio p value Hazard ratio p value 
Cytoplasmic 
p4E-BP1 
3.073 0.001 8.755 <0.0005 
Tumour size 
 
1.963 0.048 2.923 0.016 
Tumour grade 
 
0.704 0.165 0.432 0.129 
LN status 1.494 
 
0.326 4.976 0.018 
ER status 
 
1.792 0.277 1.176 0.788 
 
Table 2. Cytoplasmic p4E-BP1 is significantly associated with survival in univariate and 
multivariate regression analysis. LN – lymph node; ER – oestrogen receptor alpha 
 
 
 
 
 
Quadratic Kw 
(95% CI) 
Cytoplasmic eIF4E 
 
0.85 
(0.83 to 0.88) 
Nuclear eIF4E 
 
0.74 
(0.71 to 0.78) 
Cytoplasmic 4E-BP1 
 
0.95 
(0.94 to 0.96) 
Nuclear 4E-BP1 
 
0.93 
(0.92 to 0.95) 
Cytoplasmic 4E-BP2 
 
0.95 
(0.94 to 0.96) 
Nuclear 4E-BP2 0.91 
(0.89 to 0.92) 
Cytoplasmic p4E-BP1 
 
0.96 
(0.95 to 0.97) 
Nuclear p4E-BP1 
 
0.95 
(0.94 to 0.96) 
 
Table S1. Concordance values for the two independent scorers for each antigen and sub-cellular 
location.!Quadratic weighted kappa statistics (Kw) are shown with 95% confidence intervals 
(CI). 
! #∀!
 Cut off values  
Cytoplasmic eIF4E 4.92 
Nuclear eIF4E 4.21 
Cytoplasmic 4E-BP1 0.75 
Nuclear 4E-BP1 0.50 
Cytoplasmic 4E-BP2 0.17 
Nuclear 4E-BP2 0.17 
Cytoplasmic p4E-BP1 0.83 
Nuclear p4E-BP1 1.63 
Cytoplasmic z score 5.17 
 
 
Table S2. Cut off values determined using receiver operator curve analyses for each antigen and 
sub-cellular localisation for the end point of breast cancer recurrence. 
  
! ##!
 
 Mean DFS in months 
 (95% CI) 
 
p value 
 
Cytoplasmic 
eIF4E  
Low 145 
(116-175) 
 
 
0.120 High 199 
(168-231) 
 
Nuclear eIF4E  
Low 161 
(121-200) 
 
 
0.048 High 195 
(165-224) 
 
Cytoplasmic 
4E-BP1  
Low 225 
(198-251) 
 
 
0.007 High 119 
(101-136) 
 
Nuclear  
4E-BP1  
Low 228 
(199-256) 
 
 
0.004 High 122 
(105-139) 
 
Cytoplasmic 
4E-BP2  
Low 152 
(117-187) 
 
 
0.040 High 203 
(172-234) 
 
Nuclear  
4E-BP2  
Low 147 
(112-181) 
 
 
0.006 High 206 
(175-237) 
 
Nuclear  
p4E-BP1 
Low 212 
(188-235) 
 
 
0.008 High 99 
(79-118) 
 
Cytoplasmic z 
score 
Low 196 
(166-225) 
 
 
0.064 High 141 
(91-192) 
 
Table S3. Non-significant relationships with disease free survival (DFS) for markers. Mean 
DFS for low and high expression groups are shown (with 95% confidence intervals). Note after 
Bonferroni correction for multiple testing, a stringent threshold of p<0.003 was defined as 
indicating significance. 
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